Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., and Alvotech have announced the availability of SIMLANDI® (adalimumab-ryvk) injection in the United States. SIMLANDI® is an interchangeable biosimilar to Humira®, offering a new treatment option for a wide range of autoimmune conditions in adults, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. The medication is also approved for the treatment of juvenile idiopathic arthritis in children.
The availability of SIMLANDI® provides patients and healthcare professionals with an additional, cost-effective alternative to Humira®, expanding access to essential treatments for those living with chronic autoimmune diseases. As an interchangeable biosimilar, SIMLANDI® is expected to deliver similar efficacy and safety as the reference product, while potentially reducing the financial burden on patients and the healthcare system.
